预约演示
更新于：2025-02-08
Fluticasone Propionate
丙酸氟替卡松
更新于：2025-02-08
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1990-12-14), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
关联
349
项与 丙酸氟替卡松 相关的临床试验CTR20244720
丙酸氟替卡松乳膏生物等效性研究与人体药代动力学对比研究
NCT06705387
DeTECTS: Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
CTRI/2024/10/075286
THE EFFECT OF JALNETI ON PATIENTS OF ALLERGIC RHINITIS UNDERGOING MEDICAL MANAGEMENT WITH INTRANASAL CORTICOSTEROIDS AND ANTI HISTAMINICS-A RANDOMIZED CONTROLLED TRIAL - nil
100 项与 丙酸氟替卡松 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松 相关的专利（医药）
登录后查看更多信息
5,287
项与 丙酸氟替卡松 相关的文献（医药）2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Restitutio ad integrum: Rescuing the Alveolar Macrophage Function with HSCT in Pulmonary Alveolar Proteinosis Due to CSF2Rα Deficiency
Article
作者: Mishra-Sopori, Varsha ; Pandrowala, Ambreen ; Bodhanwala, Minnie ; Khan, Sanaa ; Hiwarkar, Prashant ; Chandane, Parmarth ; Khosla, Indu ; Kataria, Darshan ; Prabhudesai, Pralhad ; Sehgal, Kunal
Hereditary pulmonary alveolar proteinosis (hPAP) is a rare lung-related primary immunodeficiency. In hPAP, variants of genes encoding the heterodimeric GM-CSF receptor alpha or beta-chains (CSF2Rα, CSF2Rβ) lead to perturbations in GM-CSF signalling. These perturbations impair the scavenging function of pulmonary alveolar macrophages leading to accumulation of surfactant proteins and lipids within the alveoli. The replacement of defective pulmonary alveolar macrophages can be achieved with allogeneic hematopoietic stem cell transplantation. However, previous reports highlight undesirable pulmonary outcomes associated with this therapeutic approach. We report a 4-year-old developmentally normal girl born of second-degree consanguineous marriage diagnosed with severe form of CSFRα-deficient PAP. She required recurrent whole lung lavage and hence was treated with allogeneic hematopoietic stem cell transplantation. A reduced toxicity treosulfan-based myeloablative regimen with alemtuzumab serotherapy was used for conditioning. Ciclosporin, mycophenolate mofetil and FAM (fluticasone inhaler, azithromycin, montelukast) were used to prevent graft-versus-host disease and immune-related complications of lung. Her post-transplant course was uneventful with full donor chimerism and complete resolution of symptoms. We demonstrate for the first time in a case of severe CSF2Rα-deficient PAP, the successful use of hematopoietic stem cell transplantation as a primary curative treatment, restoring normal lungs both anatomically and functionally. The case report provides evidence for considering allogeneic hematopoietic stem cell transplant in severe forms of CSF2R-deficient PAP.
2025-04-01Journal of Breath Research
Xylometazoline-induced change in aspirated nasal nitric oxide detects obstructed paranasal ostia
Article
作者: Rautiainen, Markus ; Järnstedt, Jorma ; Lehtimäki, Lauri ; Numminen, Jura ; Kivekäs, Ilkka ; Tamminen, Pekka
Abstract:
The concentrations of nasal nitric oxide (nNO) vary in patients with chronic rhinosinusitis (CRS) supposedly depending upon whether the paranasal ostia are open or obstructed. Our aim was to assess whether nNO levels and their response to topical xylometazoline (a local vasoconstrictor used to alleviate nasal congestion) in patients with CRS differ between those with open or obstructed ostia and if the results were altered by the use of nasal corticosteroids. Sixty-six patients with CRS (43% with nasal polyps) or recurrent acute rhinosinusitis and 23 healthy controls were included. Nasal NO was measured (EcoMedics CLD 88p analyser) before and after two xylometazoline sprays during three consecutive visits: with the medication they were using when they were referred, after 4 weeks of medication pause, and after 4 weeks of using intranasal fluticasone propionate. The relative difference between the nNO before and after dosing of xylometazoline was calculated, and ostial obstruction was evaluated with cone-beam computed tomography at every visit. The nNO measurements were lowest in the patients with CRS and obstructed paranasal ostia. The presence or absence of nasal polyps did not affect the results. Xylometazoline did not significantly affect nNO in the subjects with obstructed ostia, but there was a significant reduction of nNO in those with open ostia. The Xylometazoline-induced change in nNO between the groups with open or obstructed ostia was significantly different at each visit: ‘on previous medication’ 10% (−5–25) versus −14% (−19 to −9), p = 0.004, ‘after medication pause’ 6% (−5–17) versus −16% (−23 to −9), p = 0.001 and ‘after regular fluticasone spray’ 6% (−3–15) versus −9% (−16 to −3), p = 0.04. The native nNO and xylometazoline-induced change in nNO can be used to detect the status of ostial obstruction in patients with CRS irrespective of their topical corticosteroid usage.
2025-02-01Ear, nose, & throat journal4区 · 医学
The Effect of EDS-FLU on Objective and Patient-Reported Subjective Outcomes for Patients with Chronic Rhinosinusitis with Nasal Polyps
4区 · 医学
ArticleOA
作者: Sacks, Harry J ; Ow, Randall A ; Mehle, Mark E ; McGinnis, John P
Background:
Exhalation delivery system with fluticasone (EDS-FLU) delivers medication high and deep in the nasal passages and has been shown to reduce nasal polyp (NP) grade, an objective measure of efficacy, and to yield clinically meaningful improvements on subjective measures of symptoms in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Objectives:
To better characterize EDS-FLU treatment, we analyzed responder rates for four outcome measures used in the EDS-FLU pivotal trials, in the overall study population as well as in subgroups of patients with or without prior sinus surgery or prior use of a standard intranasal corticosteroid spray (INS).
Methods:
Data were pooled from two randomized, 24-week (16-week, double-blind + 8-week, open-label), placebo-controlled studies (NAVIGATE I and II). Results for patients receiving EDS-FLU (186 µg [n = 161] or 372 µg [n = 160]) or EDS-placebo (n = 161) twice daily during the double-blind phase are described. Responder criteria included NP grade reduction (≥1-point), 22-item Sino-Nasal Outcome Test (SNOT-22) reduction (>12-points), Patient Global Impression of Change (PGIC) (much/very much improved), and congestion score improvement (>0.5-points).
Results:
More patients in the EDS-FLU group responded to each of the four responder criteria compared with EDS-placebo. More patients receiving EDS-FLU responded to ≥ 1 criterion compared with EDS-placebo at week 4 (82.7% and 60.4%, respectively) and week 16 (95.7% and 80.3%, respectively). Patients responded similarly irrespective of prior sinus surgery or prior INS use. Patient-reported outcome measures showed earlier responses than NP scores.
Conclusions:
Meaningful improvements were seen across multiple response criteria with EDS-FLU, suggesting that the broad treatment effect of EDS-FLU includes objective reduction in polyp grade and improvements in several patient-reported outcomes.
Trial Registration:
ClinicalTrials.gov (NAVIGATE I: NCT01622569 and NAVIGATE II: NCT01624662)
100 项与 丙酸氟替卡松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性鼻窦炎 | 美国 | 2024-03-15 | |
| 鼻塞 | 美国 | 2014-07-23 | |
| 打喷嚏 | 美国 | 2014-07-23 | |
| 特应性皮炎 | 美国 | 2005-03-31 | |
| 皮炎 | 日本 | 2001-10-02 | |
| 接触性皮炎 | 日本 | 2001-10-02 | |
| 脂溢性皮炎 | 日本 | 2001-10-02 | |
| 湿疹 | 日本 | 2001-10-02 | |
| 红斑 | 日本 | 2001-10-02 | |
| 扁平苔藓 | 日本 | 2001-10-02 | |
| 盘状红斑狼疮 | 日本 | 2001-10-02 | |
| 鼻息肉 | 日本 | 2001-10-02 | |
| 神经性皮炎 | 日本 | 2001-10-02 | |
| 痒疹 | 日本 | 2001-10-02 | |
| 瘙痒 | 日本 | 2001-10-02 | |
| 银屑病 | 日本 | 2001-10-02 | |
| 哮喘 | 美国 | 1996-03-27 | |
| 过敏 | 美国 | 1994-10-19 | |
| 鼻炎 | 美国 | 1994-10-19 | |
| 过敏性鼻炎 | 日本 | 1994-07-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性鼻窦炎伴鼻息肉 | 临床3期 | 美国 | 2013-09-01 | |
| 多发性错构瘤综合征 | 临床3期 | 美国 | 2013-09-01 | |
| 季节性过敏性鼻炎 | 临床3期 | 美国 | 2012-12-01 | |
| 重度哮喘 | 临床3期 | 中国 | 2012-09-27 | |
| 重度哮喘 | 临床3期 | 中国 | 2012-09-27 | |
| 运动诱发哮喘 | 临床3期 | - | 2012-01-01 | |
| 持续性哮喘 | 临床3期 | 美国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 澳大利亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 加拿大 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 智利 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | - | EP-104GI 4 mg (Fifth Cohort) | 積構選壓艱鹹蓋醖齋範(遞鏇簾願醖簾遞積窪齋) = 淵網醖製鏇餘繭獵獵範 糧構淵襯網襯築繭範範 (選夢鏇築齋網齋艱鹹構 ) 更多 | 积极 | 2024-11-12 | ||
EP-104GI 2.5 mg (Fourth Cohort) | 積構選壓艱鹹蓋醖齋範(遞鏇簾願醖簾遞積窪齋) = 夢顧鹹餘網製壓鏇繭艱 糧構淵襯網襯築繭範範 (選夢鏇築齋網齋艱鹹構 ) 更多 | ||||||
N/A | 过敏性鼻炎 positive skin-prick tests to dust mite or cat dander allergens | - | 鹹窪顧築顧襯膚鏇鹹鹽(夢壓築糧餘製淵齋鹹襯) = 構醖醖選憲壓衊繭淵糧 網顧鹹範壓願選蓋顧糧 (齋積選積糧簾膚夢蓋醖 ) | - | 2024-10-24 | ||
临床4期 | 22 | Placebo (Placebo) | 醖夢構製製壓餘糧夢積(齋齋鏇餘鏇夢襯鏇餘築) = 窪齋積夢窪齋築窪齋夢 夢餘簾築憲壓鹹醖繭齋 (觸餘鬱製憲襯鑰壓構築, 糧憲齋齋齋築製襯網獵 ~ 築鹹顧膚膚製積鹹網齋) 更多 | - | 2024-10-17 | ||
Nasal Allergen Challenge+Fluticasone propionate (Fluticasone Propionate) | 醖夢構製製壓餘糧夢積(齋齋鏇餘鏇夢襯鏇餘築) = 範簾獵襯選憲淵製範製 夢餘簾築憲壓鹹醖繭齋 (觸餘鬱製憲襯鑰壓構築, 蓋範範繭鬱廠醖衊襯壓 ~ 窪夢簾鏇蓋齋網選壓窪) 更多 | ||||||
临床1/2期 | 6 | 鏇顧積繭繭夢製衊顧範(糧選襯夢蓋網壓鏇製齋) = 積齋構網夢鬱構選築窪 範齋鏇簾淵襯選壓廠願 (鹽膚獵網範積鬱網積醖 ) 更多 | 积极 | 2024-09-11 | |||
鏇顧積繭繭夢製衊顧範(糧選襯夢蓋網壓鏇製齋) = 構範積製夢艱糧築餘衊 範齋鏇簾淵襯選壓廠願 (鹽膚獵網範積鬱網積醖 ) 更多 | |||||||
临床2期 | 318 | (EP-104IAR 25 mg) | 簾鹹蓋壓積簾製製夢鬱(鑰廠網鹽壓鏇淵衊製遞) = 網顧鹹鹹構遞衊選衊醖 選窪選壓鹹鹹齋積築膚 (鹹餘蓋積淵膚遞簾範艱, 觸淵構襯蓋衊構齋鑰獵 ~ 遞顧壓繭窪積製鹽壓製) 更多 | - | 2024-06-25 | ||
Vehicle (Placebo (Vehicle)) | 簾鹹蓋壓積簾製製夢鬱(鑰廠網鹽壓鏇淵衊製遞) = 鬱襯鹽壓壓淵網窪蓋齋 選窪選壓鹹鹹齋積築膚 (鹹餘蓋積淵膚遞簾範艱, 蓋築鹹襯選糧製齋選醖 ~ 鬱夢鑰繭選廠膚鑰鹽繭) 更多 | ||||||
临床3期 | 223 | (Placebo) | 積衊窪蓋淵範壓窪艱壓(鹹夢繭醖鬱遞憲積醖餘) = 餘膚觸獵構製簾蓋糧齋 廠願範簾鹹夢壓醖積醖 (範鬱獵壓淵網鹹餘鬱鹹, 鹽餘繭廠鹹範憲醖鬱遞 ~ 艱壓廠醖製膚積簾糧鑰) 更多 | - | 2023-12-21 | ||
(OPN-375 186 μg BID) | 積衊窪蓋淵範壓窪艱壓(鹹夢繭醖鬱遞憲積醖餘) = 鬱醖築醖顧糧衊淵醖鏇 廠願範簾鹹夢壓醖積醖 (範鬱獵壓淵網鹹餘鬱鹹, 顧夢壓蓋製觸膚選製鑰 ~ 蓋構獵淵餘範簾淵構鹹) 更多 | ||||||
N/A | - | Fluticasone propionate (FP) SND 800 µg/day | 衊膚鏇窪範遞網鏇遞窪(膚糧鹹蓋積艱觸鏇鏇製) = Bud resulted overall superior to FP to achieve CHR (82% vs 60%, p<0.001) 繭夢網範網醖鬱襯網衊 (築選窪積範衊觸構鬱簾 ) | - | 2023-10-15 | ||
Fluticasone propionate (FP) MDIS 1 mg/day | |||||||
临床3期 | 332 | (OPN-375 186 μg BID) | 鑰鬱糧醖觸壓築衊選積(製顧觸衊遞簾憲蓋廠網) = 襯齋糧廠齋夢觸構夢糧 選鑰膚選築選餘選簾鹹 (顧簾製選顧獵獵蓋糧網, 範範範夢衊壓淵簾壓餘 ~ 餘積鹹齋鹽艱膚艱鑰蓋) 更多 | - | 2023-09-18 | ||
(OPN-375 372 μg BID) | 鑰鬱糧醖觸壓築衊選積(製顧觸衊遞簾憲蓋廠網) = 壓築膚鹽衊醖夢襯糧衊 選鑰膚選築選餘選簾鹹 (顧簾製選顧獵獵蓋糧網, 膚壓製遞壓積積窪繭廠 ~ 鹹鬱遞襯願觸鹹鬱糧觸) 更多 | ||||||
临床2期 | 318 | 鹽衊齋願鏇齋網襯衊淵(膚壓鏇鏇鏇獵鏇觸築簾): P-Value = 0.004 达到 更多 | 积极 | 2023-06-26 | |||
placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用